1978
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologic
1966
Preliminary clinical studies with ibenzmethyzin
DeVita V, Serpick A, Carbone P. Preliminary clinical studies with ibenzmethyzin. Clinical Pharmacology & Therapeutics 1966, 7: 542-546. PMID: 5939977, DOI: 10.1002/cpt196674542.Peer-Reviewed Original ResearchConceptsBone marrow depressionDaily oral dosesBone marrow toxicityPreliminary clinical studyMarrow depressionHodgkin's diseaseOral dosesWeekly injectionsMarrow toxicityAdverse reactionsMalignant melanomaOral administrationClinical studiesNeoplastic diseasePatientsAntitumor activityDiseaseNauseaVomitingSomnolenceNeurologicMelanomaAtaxiaAdministrationDose